Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Fludarabine/Melphalan"'
Autor:
C. Reid, Y. Lwin, William Stevenson, Kelly Wong, Julian Lindsay, M. Greenwood, Christopher Arthur, Keith Fay, Ian Kerridge
Publikováno v:
Bone Marrow Transplantation. 55:1638-1641
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09ccaddc04632702ac158570fa1729d6
https://doi.org/10.1038/s41409-019-0713-z
https://doi.org/10.1038/s41409-019-0713-z
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ryan J. Caddell, Brian C. Betts, Jun-Min Zhou, Janelle Perkins, Farhad Khimani, Taiga Nishihori, Asmita Mishra, Joseph Pidala, Elizabeth DiMaggio, Claudio Anasetti, Lia Perez, Hugo F. Fernandez, Rebecca Tombleson
Publikováno v:
Leukemialymphoma. 61(7)
Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc290b9dece0c6b1f98fd8e470ecb639
https://pubmed.ncbi.nlm.nih.gov/32476524
https://pubmed.ncbi.nlm.nih.gov/32476524
Autor:
Sebastian Mayer, Mateo Mejia Saldarriaga, Jingmei Hsu, Pinkal Desai, Sangmin Lee, Koen van Besien, Alexandra Gomez-Arteaga, Yassine Tahri, Ellen K. Ritchie, Danielle Guarneri, Michael B. Samuel, Adrienne A. Phillips, Zhengming Chen, Gail J. Roboz, Tsiporah B. Shore
Publikováno v:
Blood. 138:4833-4833
Introduction: Acute myeloid leukemia (AML) is heterogenous disease with a range of cytogenetic and molecular changes. Several molecular mutations identified in AML patients at diagnosis have prognostic implications and play important roles in guiding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd1870e48e43ff590765467bd3fb0e23
https://doi.org/10.1182/blood-2021-149297
https://doi.org/10.1182/blood-2021-149297
Autor:
Michael R. Bishop, James L. LaBelle, Hongtao Liu, Justin Kline, Amy Wang, Wendy Stock, Bulent Aydogan, Peter A. Riedell, Yasmin Hasan, Richard A. Larson, Andrew S. Artz, Kamil M. Yenice, Satyajit Kosuri, J. Partouche
Publikováno v:
Blood. 136:39-40
Background: Treatment options for relapse after allo-SCT remain limited with poor outcomes. Second Allo-SCT provides benefit to a small subset of patients (pts). However, relapse rates after second Allo-SCT are high and novel approaches to improve ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3486ef56ace191736352615739bc78b6
https://doi.org/10.1182/blood-2020-138554
https://doi.org/10.1182/blood-2020-138554
Autor:
A. Kin, Voravit Ratanatharathorn, Seongho Kim, Abhinav Deol, J. Chi, L. Ayash, Dipenkumar Modi, Joseph P. Uberti, Asif Alavi
Publikováno v:
Annals of Oncology. 31:S656
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b6de304534a33891975d01dd37796b8
https://doi.org/10.1016/j.annonc.2020.08.023
https://doi.org/10.1016/j.annonc.2020.08.023
Autor:
J. Riemann, S. Lindner, F. Lang, Saskia Gueller, Gesine Bug, Hubert Serve, Hans Martin, J. Steinmann, Salem Ajib, T. Berg, Zuzana Jedlickova, R. Toenges
Publikováno v:
HemaSphere. 3:476-477
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a708495a0013741748fc087125c11d8
https://doi.org/10.1097/01.hs9.0000562512.06403.a5
https://doi.org/10.1097/01.hs9.0000562512.06403.a5
Autor:
Shingo Yano, Kaoru Kahata, Koji Iwato, Tetsuya Eto, Yoshiko Atsuta, Tadakazu Kondo, Heiwa Kanamori, Shinichi Kako, Koji Kawamura, Jun Aoki, Ken Ishiyama, Yukiyasu Ozawa, Shuichi Mizuta, Masashi Sawa, Naoyuki Uchida, Takahiro Fukuda, Yoshinobu Kanda, Tatsuo Ichinohe
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 23(12)
The optimal conditioning regimen for elderly patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) remains unclear. We retrospectively analyzed 1607 patients aged 50 years or older with acute myeloid leukemia (AML), acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c102d7b73789edef70b0588a983c3496
https://pubmed.ncbi.nlm.nih.gov/28890406
https://pubmed.ncbi.nlm.nih.gov/28890406
Autor:
Marina Konopleva, Marcos de Lima, Qaiser Bashir, Julianne Chen, Issa F. Khouri, Antonio Di Stasi, Gheath Alatrash, Amir Hamdi, Sai Ravi Pingali, Partow Kebriaei, Chitra Hosing, Muzaffar H. Qazilbash, LM Poon, Stefan O. Ciurea, Denái R. Milton, Richard E. Champlin, Betul Oran, Gabriela Rondon, Katayoun Rezvani, Elizabeth J. Shpall, Piyanuch Kongtim, Uday R. Popat, Dean A. Lee, Amin M. Alousi, Sairah Ahmed
Publikováno v:
Biology of Blood and Marrow Transplantation. 20:1975-1981
Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been performed primarily with an HLA-matched donor. Outcomes of haploidentical transplantation have recently improved, and a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e5ce885def9d533899d65efba35e977
https://doi.org/10.1016/j.bbmt.2014.08.013
https://doi.org/10.1016/j.bbmt.2014.08.013
Publikováno v:
Bone Marrow Transplantation. 49:248-253
MTX is a standard component of acute GVHD prophylaxis. However, its use can be limited by toxicity. On the basis of disease risk, we prospectively assigned 132 consecutive patients from January 2005 to February 2011 undergoing first allogeneic hemato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445a6dd406b6ded436c41ae97abc6768
https://doi.org/10.1038/bmt.2013.167
https://doi.org/10.1038/bmt.2013.167